Thousand Oaks / California / United States
Gregory P. Fontana, MD is an international leader in cardiothoracic surgery, whose primary professional focus has been on less invasive approaches to the treatment of structural heart disease. He previously served as Managing Director of the Heart and Vascular Institute and Chairman of the Department of Cardiothoracic Surgery at Lenox Hill Hospital in New York City, Vice Chairman of Surgery and attending cardiac surgeon at Cedars Sinai Medical Centers Heart Institute in Los Angeles and as Clinical Professor of Surgery at the David Geffen School of Medicine at UCLA. Dr. Fontana has been a pioneer and principal investigator for several minimally invasive approaches in cardiac surgery involving transcatheter valve therapies and minimally invasive surgical procedures for congenital and acquired heart disease. Among many others, he has been a principal investigator in the Partner Trial of transcatheter aortic valve implantation, the CoreValve Pivotal trial, the Medtronic Low-Risk TAVR Trial, and the Perceval trial of sutureless aortic valves, and is currently the national principal investigator for the St. Jude Transcatheter Portico Valve IDE Pivotal trial. As a widely published researcher and author, Dr. Fontanas contributions to medical literature includes more than 150 academic citations including articles, book chapters and reviews.
